Blacktown Pharmacy department is involved in a range of medication and practice related research activities. The vision of the pharmacy department is to lead research activities under the broad theme of Quality Use of Medicines (QUM), which includes medication safety, therapeutics, pharmacy practice research, and health-outcomes research.
The department is involved in a wide range of research studies, including collaboration with researchers from Sydney University and investigator-initiated practice evaluation program.
Current research studies include
The main goals are
Medication regimen complexity and adherence in pre-dialysis patients
Psychosocial interventions affecting patients with end-stage kidney disease
Antimicrobial stability studies in various peritoneal dialysis solutions
Quality use of medicines in patients with kidney disease
Audit of drug-induced acute kidney injury (AKI) cases at Blacktown Hospital
Impact of Hospitalisation on anticholinergic burden and medication regimen complexity in patients admitted under the geriatrics department
Clinical trials including haematology, oncology, endocrinology and respiratory
Pharmacy team-based Medication Reconciliation in the Emergency Department (collaboration between WSLHD, SLHD and Sydney University)
Improved management with better clinical efficiency
Better health outcomes through interventions
- Stability of Meropenem and Piperacillin/Tazobactam with Heparin in Various Peritoneal Dialysis Solutions. Mendes K, Harmanjeet H, Sedeeq M, Modi A, Wannady T, Zaidi STR, Ming LC, Castelino RL, Sud K, Peterson GM, Patel RP. Peritoneal Dialysis International 2018, 38 (6): 430-440.
- Stability of Ceftazidime and Heparin in four different types of peritoneal dialysis solutions. Kandel S, Zaidi STR, Ming LC, Castelino RL, Sud K, Patel RP. Peritoneal Dialysis International 2018, 38 (1): 49-56.
- Stability of Tigecycline in different types of peritoneal dialysis solutions. Robiyanto R, Zaidi ST, Shastri MD, Castelino RL, Wanandy ST, Jose MD, Patel RP. Peritoneal Dialysis International 2016, 36 (4): 410-4
- Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia-need for a higher than recommended weight-based dosing. Castelino RL, Maddula M, Tarafdar ST, Sud K, Kairaitis L. Haemodialysis International 2018.
Looking for General